TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9799030
Drug: C-group (N
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-group (N = 15), which did not receive therapy
Study: 30075748
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice daily
Study: 2391738
Drug: Ciprofloxacin 1000
Normalized name: ciprofloxacin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1000 mg twice daily
Study: 26264702
Drug: Evacetrapib 100
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib 100 mg
Study: 26264702
Drug: Evacetrapib 300
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib 300 mg
Study: 21679043
Drug: IV diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV diclofenac 3.75 mg
Study: 21679043
Drug: IV diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV diclofenac 75 mg
Study: 19628193
Drug: Overall patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall patients (statin treatments)
Study: 16641127
Drug: Echinacea treatment
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea treatment for rhinovirus infection
Study: 9423108
Drug: Thiopentone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4 mg/kg)
Study: 14625336
Drug: 8 days
Normalized name: rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 days of antibiotic therapy
Study: 14625336
Drug: 15 days
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 days of antibiotic therapy
Study: 28235529
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine plus 2 μg/kg dexmedetomidine, 1 mL/kg
Study: 28235529
Drug: 0.125% bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine, 1 mL/kg
Study: 24203450
Drug: ZST (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZST (1.0 mg)
Study: 24203450
Drug: ZST (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZST (1.75 mg)
Study: 24203450
Drug: ZST (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZST (3.5 mg)
Study: 20494961
Drug: Fulvestrant approved
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant approved dose (AD)
Study: 20494961
Drug: Fulvestrant loading
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant loading dose (LD)
Study: 20494961
Drug: Fulvestrant high
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant high dose (HD)
Study: 1258750
Drug: Intramuscular lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular lidocaine (4.5 mg/kg)
Study: 28718248
Drug: 2% diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% diltiazem cream
Study: 28718248
Drug: 0.2% glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% glyceryl trinitrate cream
Study: 21606974
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg A3309
Study: 21606974
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg A3309
Study: 21876564
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg A3309
Study: 22878195
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of Pueraria flower extract (PFE)
Study: 22878195
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of Pueraria flower extract (PFE)
Study: 12654763
Drug: telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telithromycin 800 mg once daily
Study: 9793807
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl (25 micrograms) with prior i.v. fluid (500 ml of lactated Ringer's solution)
Study: 9793807
Drug: Fluid infusion
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid infusion (500 ml of lactated Ringer's solution)
Study: 7648764
Drug: E3810 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: E3810 (20 mg once daily for 7 days)
Study: 7648764
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg once daily for 7 days)
Study: 2771866
Drug: Disopyramide single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide single bolus injection (150 mg) over 5 min
Study: 2771866
Drug: Disopyramide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide infusion (28.2 mg/h to steady state)
Study: 2771866
Drug: Disopyramide single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide single bolus injection (150 mg)
Study: 12078386
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 3 g vitamin C
Study: 12078386
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml 0.9% saline solution (placebo)
Study: 28877944
Drug: External inspections
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External inspections of sepsis detection and treatment
Study: 27212612
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis before skin incision (A)
Study: 27212612
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis after umbilical cord clamping (C)
Study: 16375216
Drug: Mouth dissolving
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouth dissolving tablets (Nimulid-MD)
Study: 16375216
Drug: Nimulid suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimulid suspension
Study: 16375216
Drug: Mouth dissolving
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouth dissolving tablets
Study: 10206567
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment (home-study manual)
Study: 2930443
Drug: Structured research-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured research-based marital therapy
Study: 2930443
Drug: Clinically flexible
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically flexible marital therapy
Study: 21742301
Drug: Intralesional methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intralesional methotrexate infiltration (single dose)
Study: 19738565
Drug: Transcranial magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial magnetic therapy (TcMT), 10 sessions, bitemporal method, modulation frequency 1-10 Hz
Study: 16320011
Drug: Catheter‐mediated femoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter‐mediated femoral nerve block with 1% prilocaine (40 ml) and post‐operatively 0.2% ropivacaine (30 ml) 6 hourly
Study: 16320011
Drug: Intravenous metamizol
Normalized name: Metamizole
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metamizol (1 g) and oral tilidine (100 mg) + naloxone (8 mg), with reduced doses for patients aged 90 years or more
Study: 14571608
Drug: Composite Rhodiolae
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite Rhodiolae (CR) administered 4 g daily for 7-10 days before and 5-7 days after the operation
Study: 8985019
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg i.v. weekly with forced hydration during radiotherapy (CM group)
Study: 1478406
Drug: Mesalazine controlled-release
Normalized name: mesalamine Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine controlled-release suppository 1 g once daily
Study: 6141898
Drug: SKF 93479
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF 93479 (20, 40, 60, and 80 mg)
Study: 6141898
Drug: SKF 93479
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF 93479 (80 mg)
Study: 27273941
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with docetaxel and cisplatin and three‐dimensional conformal radiotherapy
Study: 18072836
Drug: Gain-framed messages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gain-framed messages with sustained-release bupropion (300 mg/day) for 7 weeks
Study: 18072836
Drug: Loss-framed messages
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loss-framed messages with sustained-release bupropion (300 mg/day) for 7 weeks
Study: 15449047
Drug: 131I administration
Normalized name: iobenguane (131I)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 131I administration (3.7 GBq)
Study: 15449047
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro irradiation at doses of 0.5, 1 and 2 Gy
Study: 12403316
Drug: ICP10deltaPK vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP10deltaPK vaccine
Study: 10235427
Drug: Napsagatran 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Napsagatran 5 mg/h and 9 mg/h
Study: 1887351
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg gentamicin
Study: 1887351
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg gentamicin
Study: 1887351
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg gentamicin
Study: 6651314
Drug: Oral methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methoxsalen and total body irradiation
Study: 6651314
Drug: Topical applications
Normalized name: honey based topical applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical applications of methoxsalen or oral methoxsalen combined with local irradiation of the scalp
Study: 6651314
Drug: PUVA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA treatment (psoralens and UV‐A)
Study: 23020819
Drug: Probiotic-containing powder
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic-containing powder (daily dose of minimum 1 billion colony-forming units of Lactobacillus rhamnosus LGG® and Bifidobacterium animalis ssp. lactis BB-12®), n=114
Study: 15311008
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate (400 mg calcium twice daily)
Study: 15311008
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate (20 mEq twice daily)
Study: 15311008
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate and potassium citrate (at same doses)
Study: 29743101
Drug: Perioperative, algorithm-driven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative, algorithm-driven hemodynamic therapy based on individualized fluid status and cardiac output optimization using pulse-pressure variation (PPV) and pulse-contour analysis (ProAQT© device).
Study: 29743101
Drug: Standard local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard local care based on established basic hemodynamic treatment.
Study: 29743101
Drug: Perioperative, algorithm-driven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative, algorithm-driven hemodynamic therapy.
Study: 24712855
Drug: Parent-focused treatment
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-focused treatment
Study: 24712855
Drug: Conjoint family‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint family‐based treatment
Study: 22993169
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance (OA) therapy
Study: 19086875
Drug: Desvenlafaxine succinate
Normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine succinate (DVS) at doses ranging from 50 to 400 mg/day
Study: 8358407
Drug: Individualized oral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized oral hygiene instruction and dental supplies (dental mirror and red disclosing tablets)
Study: 8358407
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral hygiene instruction or supplies (Control)
Study: 2439823
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg bopindolol
Study: 26754303
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg paroxetine controlled-release tablet
Study: 26754303
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg paroxetine controlled-release tablet
Study: 26754303
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg paroxetine controlled-release tablet
Study: 22897903
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity program set at home using pedometers
Study: 18596310
Drug: Glutamine dipeptide-supplemented
Normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine dipeptide-supplemented parenteral nutrition (GLN-PN)
Study: 9096188
Drug: Teicoplanin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (6 mg/kg every 12 h for three doses then daily)
Study: 9096188
Drug: Flucloxacillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin (1 g every 6 h i.v./p.o.)
Study: 8212206
Drug: EC solution
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC solution
Study: 30260145
Drug: Stem cells
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cells therapy in addition to surgical left ventricular restoration (SVR)
Study: 9041468
Drug: Intramuscular interferon-beta
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon-beta (IFN-beta) at a dosage of 6 million units three times per week for 6 months
Study: 9041468
Drug: Intramuscular interferon-beta
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon-beta (IFN-beta)
Study: 7701045
Drug: Ipsapirone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone 10 mg
Study: 26174461
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg daily, increased to 100 mg after 1 week)
Study: 18286296
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB), 1.25 mg, 5‐7 days before PPV
Study: 16448519
Drug: Metformin-glibenclamide 500/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin-glibenclamide 500/2.5 mg tablets (initial daily dose 1000/5 mg)
Study: 16448519
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg plus rosiglitazone 4 mg (initial daily dose 1000-2000 mg + 4 mg)
Study: 16448519
Drug: Metformin-glibenclamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin-glibenclamide
Study: 2667746
Drug: Adjuvant progestagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant progestagen therapy (progesterone)
Study: 17476008
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no additional therapy)
Study: 1069314
Drug: 250 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mcg/kg N,N-Dimethyltryptamine (DMT) i.m.
Study: 31121324
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg every 2 weeks) until progression, unacceptable toxicity, or consent withdrawal
Study: 26041274
Drug: Immediate injection
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate injection of botulinum toxin type A (group A)
Study: 26041274
Drug: 1-month delayed
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month delayed injection of botulinum toxin type A (group B)
Study: 25099322
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol-remifentanil
Study: 22230384
Drug: Enalapril-FA tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril-FA tablet (10:0.4 mg, low FA group)
Study: 22230384
Drug: Enalapril-FA tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril-FA tablet (10:0.8 mg, high FA group)
Study: 22085872
Drug: Enalapril only
Normalized name: Enalapril only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril only (10 mg, control group)
Study: 16192600
Drug: YES-ASP (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: YES-ASP (20 weekly doses of high-dose L-asparaginase at 25,000 IU/m2)
Study: 16192600
Drug: NO-ASP (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO-ASP (no high-dose L-asparaginase)
Study: 9806581
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of chlamydial RNA molecules
Study: 8961907
Drug: Sulfasalazine (SSZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine (SSZ) at a dosage of 2,000 mg/day
Study: 3100007
Drug: Diltiazem 240
Normalized name: diltiazem 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 240 mg
Study: 7295884
Drug: Sustained-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release isosorbide dinitrate (30 mg) in combination with standard-release pindolol (7.5 mg)
Study: 7295884
Drug: Standard-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-release isosorbide dinitrate alone (30 mg)
Study: 7295884
Drug: Standard-release pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-release pindolol alone (7.5 mg)
Study: 7295884
Drug: Sustained-release pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release pindolol (7.5 mg) in combination with isosorbide dinitrate
Study: 28116754
Drug: Esoxx (hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esoxx (hyaluronic acid-chondroitin sulphate based bioadhesive formulation) plus standard dose PPIs
Study: 28116754
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard dose PPIs
Study: 28116754
Drug: Esoxx plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esoxx plus standard dose PPIs
Study: 21811062
Drug: Dried California
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried California Mission figs (120 g/day) added to usual diet for 5 weeks
Study: 19455481
Drug: Recovery beverage
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery beverage (40 g CHO + 20 g PRO)
Study: 15549278
Drug: SSRI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI treatment (paroxetine or citalopram) for 4 weeks
Study: 6497566
Drug: Haloperidol (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (fixed doses)
Study: 20442660
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg kg(‐1)
Study: 20442660
Drug: Remifentanil doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil doses (3, 4, 5, or 6 microg kg(‐1))
Study: 15472910
Drug: Oral Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Etoposide
Study: 15472910
Drug: 3-drug combination
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-drug combination (actinomycin-D, vincristine, bleomycin)
Study: 2007841
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg b.i.d. for 2 weeks followed by 10 mg b.i.d. for a further 2 weeks)
Study: 6442151
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg or 500 mg, 12-hourly for 10 days
Study: 29366703
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of bivalent HPV vaccine
Study: 26084406
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g/8 hours) plus Daptomycin (6 mg/kg/day)
Study: 26084406
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g/8 hours)
Study: 23727737
Drug: Control (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.04 ml distilled water)
Study: 21995695
Drug: Doxazosin gastrointestinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin gastrointestinal therapeutic system (GITS) 4 mg
Study: 8788832
Drug: Discarding 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discarding 1.5 ml of blood from the catheter
Study: 6131635
Drug: Almitrine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (0.5 mg/kg/h for 2 h)
Study: 16344401
Drug: PV isolation
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PV isolation in combination with linear ablation joining the 2 superior PVs (roofline)
Study: 7879931
Drug: Intraperitoneal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal morphine (1 mg in 20 ml saline)
Study: 7879931
Drug: Intraperitoneal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal saline and 1 mg intravenous morphine
Study: 7879931
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine (20 ml 0.25%)
Study: 7879931
Drug: Interpleural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpleural morphine (1.5 mg in 30 ml saline)